Ventyx Biosciences Completes Enrollment In Phase 2 Trial Of VTX002 In Ulcerative Colitis & Phase 2 SERENITY Trial Of VTX958 In Plaque Psoriasis, With Topline Data Expected In Early Q4 And Q4 2023, Respectively
Portfolio Pulse from Benzinga Newsdesk
Ventyx Biosciences has completed enrollment for its Phase 2 trials of VTX002 in ulcerative colitis and VTX958 in plaque psoriasis. Topline data for both trials are expected in early Q4 and Q4 2023, respectively.
June 07, 2023 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ventyx Biosciences completed enrollment for Phase 2 trials of VTX002 and VTX958, with topline data expected in Q4 2023.
The completion of enrollment for the Phase 2 trials of VTX002 and VTX958 is a positive milestone for Ventyx Biosciences. Positive topline data from these trials could lead to further development and potential approval of the drugs, which would be beneficial for the company's stock price. The news is highly relevant and important for investors in VTYX, and the confidence in the analysis is high due to the direct impact on the company's pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100